Eutilex Co. Ltd. announced that it has appointed Agustin de la Calle, Ph.D., as chief business officer. In this capacity, Dr. de la Calle will focus on the establishment of licensing, co-development, joint research and investment opportunities involving Eutilex's preclinical and clinical-stage pipeline of immuno-oncology candidates. He will report to Byoung S. Kwon, Ph.D., the company's founder and CEO.  Dr. de la Calle has close to 20 years of business development experience with international companies in the biotechnology and pharmaceutical industry. Prior to joining Eutilex, Dr. de la Calle was an executive consultant for Korea Health Industry Development Institute, a division of the South Korean government. Previously, he served as vice president of business development for Gemmus Pharmaceuticals. Earlier in his career, he was vice president of corporate and business development at The NDA Group.